Evaluation of Helicobacter species in inflammatory bowel disease.

abstract：BACKGROUND:H2-receptor antagonists are becoming widely available as over-the-counter medications for the treatment of heartburn and excess gastric acidity. AIM:To determine the effects of single low doses of ranitidine on intragastric acidity. METHODS:Intragastric pH was measured for 9 h after lunch in five studies i...

journal_title：Alimentary pharmacology & therapeutics

authors： Wyeth JW,Pounder RE,Sercombe JC,Snell CC

更新日期：1998-03-01 00:00:00

abstract：BACKGROUND:Non-alcoholic fatty liver disease generally has a benign course; however, patients with non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma. Currently, there is a lack of consensus about optimal NASH treatment. AIM:To assess the efficacy of insulin-sensitizing agents ...

journal_title：Alimentary pharmacology & therapeutics

authors： Rakoski MO,Singal AG,Rogers MA,Conjeevaram H

更新日期：2010-11-01 00:00:00

abstract：:In a Swedish double-blind multicentre study, omeprazole (30 mg o.m.) was compared with the H2-receptor antagonist cimetidine (400 mg b.d.) in 152 patients. Clinical assessments and laboratory investigations were carried out at 2 and 4 weeks, and again at 6 weeks in unhealed patients. Endoscopy was performed at 2 weeks...

journal_title：Alimentary pharmacology & therapeutics

authors： Dahlgren S,Domellöf L,Hradsky M,Norryd C,Brunkwall J,Svensson G,Svensson JO,Karlsson J,Knutson U,Gasslander T

更新日期：1988-12-01 00:00:00

abstract：BACKGROUND:Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis. AIM:To evaluate the efficacy of mesalazine suppositories in patients with ulcerative colitis (UC) and rectal inflammation; and in patient groups categorised by the extent...

journal_title：Alimentary pharmacology & therapeutics

authors： Watanabe M,Nishino H,Sameshima Y,Ota A,Nakamura S,Hibi T

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:In Sweden, the most common causes of liver cirrhosis are alcohol overconsumption and hepatitis C. However, recent data on the clinical characteristics of Swedish patients with cirrhosis are scarce. AIMS:To determine the incidence, clinical presentation, aetiological spectrum and survival rates of liver cirr...

journal_title：Alimentary pharmacology & therapeutics

authors： Nilsson E,Anderson H,Sargenti K,Lindgren S,Prytz H

更新日期：2016-06-01 00:00:00

abstract：BACKGROUND:One-week low-dose proton pump inhibitor-based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection. AIM:To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabeprazole and a new fluo...

journal_title：Alimentary pharmacology & therapeutics

authors： Cammarota G,Cianci R,Cannizzaro O,Cuoco L,Pirozzi G,Gasbarrini A,Armuzzi A,Zocco MA,Santarelli L,Arancio F,Gasbarrini G

更新日期：2000-10-01 00:00:00

abstract：BACKGROUND:Restriction of dietary FODMAP intake can alleviate symptoms in patients with irritable bowel syndrome. Because many FODMAPs have prebiotic actions, there is concern that their dietary restriction leads to dysbiosis with health consequences, and their intake is being encouraged by addition to foods and via su...

journal_title：Alimentary pharmacology & therapeutics

authors： Gibson PR,Halmos EP,Muir JG

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:The most commonly used second-line Helicobacter pylori eradication regimens are bismuth-containing quadruple therapy and levofloxacin-containing triple therapy, both offering suboptimal results. Combining bismuth and levofloxacin may enhance the efficacy of rescue eradication regimens. AIMS:To evaluate the ...

journal_title：Alimentary pharmacology & therapeutics

authors： Gisbert JP,Romano M,Gravina AG,Solís-Muñoz P,Bermejo F,Molina-Infante J,Castro-Fernández M,Ortuño J,Lucendo AJ,Herranz M,Modolell I,Del Castillo F,Gómez J,Barrio J,Velayos B,Gómez B,Domínguez JL,Miranda A,Martorano M

更新日期：2015-04-01 00:00:00

abstract：BACKGROUND:ONO-2952 is a novel and selective inhibitor of translocator protein 18 kDa that reduces stress-induced defecation and visceral hyperalgesia in rat models. AIM:To evaluate the efficacy and safety of ONO-2952 in females with irritable bowel syndrome with diarrhoea in an exploratory proof-of-concept study. ME...

journal_title：Alimentary pharmacology & therapeutics

authors： Whitehead WE,Duffy K,Sharpe J,Nabata T,Bruce M

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:Despite similar clinical symptoms, collagenous colitis (CC) and lymphocytic colitis (LC) are considered two distinct disease entities. AIM:To compare pathoanatomical findings, clinical presentations, risk factors, course of diseases and response to treatment in CC and LC to establish whether they could be s...

journal_title：Alimentary pharmacology & therapeutics

authors： Rasmussen MA,Munck LK

更新日期：2012-07-01 00:00:00

abstract：BACKGROUND:Recently a new 'all in one' single capsule with the three components of bismuth-based triple therapy became available in trials for treating Helicobacter pylori. AIM:To investigate the efficacy and tolerability of this new capsule when combined with lansoprazole. METHODS:A total of 66 consecutive infected ...

journal_title：Alimentary pharmacology & therapeutics

authors： De Boer WA,Van Etten RJ,Van De Wouw BA,Schneeberger PM,Van Oijen AH,Jansen JB

更新日期：2000-01-01 00:00:00

abstract：BACKGROUND:Malnutrition/sarcopenia and frailty are common in patients with cirrhosis and are associated with poor outcomes. AIM:To provide an overview of data on the importance, assessment and management of malnutrition/sarcopenia and frailty in cirrhosis. METHODS:A literature search was conducted in PubMed and other...

journal_title：Alimentary pharmacology & therapeutics

authors： Bunchorntavakul C,Reddy KR

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Saccharomyces boulardii, a well-studied probiotic, can be effective in inflammatory gastrointestinal diseases with diverse pathophysiology, such as inflammatory bowel disease (IBD), and bacterially mediated or enterotoxin-mediated diarrhoea and inflammation. AIM:To discuss the mechanisms of action involved ...

journal_title：Alimentary pharmacology & therapeutics

authors： Pothoulakis C

更新日期：2009-10-15 00:00:00

abstract：BACKGROUND:Proton pump inhibitor (PPI) therapy is known to suppress gastric acid secretion. Thus PPI therapy may decrease gastric volume and gastric contents available for gastro-oesophageal reflux by decreasing acid secretion. AIM:To determine the effect of PPI therapy on the gastric volume after a standard meal. ME...

journal_title：Alimentary pharmacology & therapeutics

authors： Babaei A,Bhargava V,Aalam S,Scadeng M,Mittal RK

更新日期：2009-04-15 00:00:00

abstract：BACKGROUND:Proton pump inhibitors have been found to be effective in numerous studies in patients with peptic ulcer disease, particularly associated with Helicobacter pylori and gastro-oesophogeal reflux disorders. Optimal healing rates of antisecretory therapy for peptic acid disease is dependent upon the degree and d...

journal_title：Alimentary pharmacology & therapeutics

authors： Blum RA,Hunt RH,Kidd SL,Shi H,Jennings DE,Greski-Rose PA

更新日期：1998-04-01 00:00:00

abstract：BACKGROUND:The epidemiology and pathophysiology of non-erosive gastro-oesophageal reflux disease differs from erosive gastro-oesophageal reflux disease. There is a possibility that non-erosive gastro-oesophageal reflux disease treatment requires a different regimen/approach but it is not yet acknowledged. AIM:To inves...

journal_title：Alimentary pharmacology & therapeutics

authors： Wada T,Sasaki M,Kataoka H,Tanida S,Itoh K,Ogasawara N,Oshima T,Togawa S,Kubota E,Yamada T,Mori Y,Fujita F,Ohara H,Nakao H,Sobue S,Joh T,Itoh M

更新日期：2005-06-01 00:00:00

abstract：BACKGROUND:Adalimumab, at an induction dose of 160/80 mg followed by 40 mg every other week is approved for treatment of refractory Crohn's disease (CD) and for patients with loss of response to infliximab. AIM:To evaluate the indications for adalimumab, the proportion of inflammatory bowel disease patients who requir...

journal_title：Alimentary pharmacology & therapeutics

authors： Swaminath A,Ullman T,Rosen M,Mayer L,Lichtiger S,Abreu MT

更新日期：2009-02-01 00:00:00

abstract：BACKGROUND:Faecal calprotectin is a reliable tool for predicting Crohn's disease (CD) relapse in patients with sustained remission. Prediction of relapse with faecal calprotectin has been less studied in patients with severe CD treated with anti-TNF. AIM:To identify an association between faecal calprotectin concentra...

journal_title：Alimentary pharmacology & therapeutics

authors： Laharie D,Mesli S,El Hajbi F,Chabrun E,Chanteloup E,Capdepont M,Razaire S,de Lédinghen V,Zerbib F

更新日期：2011-08-01 00:00:00

abstract：BACKGROUND:Patient-reported outcome (PRO) measures historically used in inflammatory bowel disease have been considered inadequate to support future drug labelling claims by regulatory agencies. AIMS:To develop PRO tools for use in Crohn's disease (CD) and ulcerative colitis (UC) following guidance issued by the US FD...

journal_title：Alimentary pharmacology & therapeutics

authors： Dulai PS,Jairath V,Khanna R,Ma C,McCarrier KP,Martin ML,Parker CE,Morris J,Feagan BG,Sandborn WJ

更新日期：2020-06-01 00:00:00

abstract：BACKGROUND:There is expanding interest in the role that diet plays in ileoanal pouch function and in the pathogenesis of pouchitis. AIMS:To present a narrative review of published literature regarding the relationship of diet with pouch function and the pathogenesis of pouchitis, and to provide potentially beneficial ...

journal_title：Alimentary pharmacology & therapeutics

authors： Ardalan ZS,Yao CK,Sparrow MP,Gibson PR

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:Symptoms of irritable bowel syndrome are often cyclical and thus may require repeated rather than continuous therapy. Tegaserod is effective and well-tolerated for irritable bowel syndrome with constipation but data on retreatment are lacking. AIM:To assess whether tegaserod retreatment is as efficacious an...

journal_title：Alimentary pharmacology & therapeutics

authors： Müller-Lissner S,Holtmann G,Rueegg P,Weidinger G,Löffler H

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:Proton pump inhibitor (PPI) use may alter the gut microbiome and increase the risk of cholangitis. However, the association of PPI use with the risk of incident cholangitis has not been evaluated. AIM:To evaluate whether PPI use was associated with a higher risk of cholangitis. METHODS:This cohort study in...

journal_title：Alimentary pharmacology & therapeutics

authors： Min YW,Kang D,Shin JY,Kang M,Park JK,Lee KH,Lee JK,Lee KT,Rhee PL,Kim JJ,Guallar E,Cho J,Lee H

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:Health-related quality of life (HRQL) is often diminished in patients with ulcerative colitis. AIM:To evaluate the effects of vedolizumab on HRQL in patients with ulcerative colitis. METHODS:Using maintenance phase data from the GEMINI 1 study, an analysis of covariance model was used to calculate mean dif...

journal_title：Alimentary pharmacology & therapeutics

authors： Feagan BG,Patel H,Colombel JF,Rubin DT,James A,Mody R,Lasch K

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:There is a lack of evidence for the efficacy of preventive medications for peptic ulcers (PUs) among long-term users of non-steroidal anti-inflammatory drugs (NSAIDs) in Japan. AIM:To estimate the preventive effect by normal dose, not high-dose histamine-H2 receptor antagonists (H2RA) for NSAID-induced ulce...

journal_title：Alimentary pharmacology & therapeutics

authors： Miyake K,Ueki N,Suzuki K,Shinji Y,Kusunoki M,Hiratsuka T,Nishigaki H,Tatsuguchi A,Futagami S,Wada K,Tsukui T,Nakajima A,Yoshino S,Sakamoto C

更新日期：2005-06-01 00:00:00

abstract：BACKGROUND:A simulated upper gastrointestinal (UGI) bleed in cirrhotic patients has been shown to induce hyperammonaemia. The kidney was the site of this exaggerated ammoniagenesis with alanine as substrate. Administration of alanine to decompensated cirrhotic patients did not change hepatic gluconeogenesis, but result...

journal_title：Alimentary pharmacology & therapeutics

authors： Mpabanzi L,Deutz N,Hayes PC,Dejong CH,Olde Damink SW,Jalan R

更新日期：2012-04-01 00:00:00

abstract：BACKGROUND:Crohn's disease (CD) has a high-risk of bowel resection and later surgery for recurrent disease. Recent guidelines recommend colonoscopy 6-12 months following surgery to reduce further surgical intervention through medical therapy intensification. AIMS:To investigate the risk of further surgery at the anast...

journal_title：Alimentary pharmacology & therapeutics

authors： King D,Coupland B,Dosanjh A,Cole A,Adderley NJ,Reulen RC,Patel P,Trudgill NJ

更新日期：2021-01-01 00:00:00

abstract：BACKGROUND:Cirrhotic patients with spontaneous bacterial peritonitis (SBP) have elevated rates of renal impairment and mortality. It has been shown that cefotaxime plus albumin infusion decrease renal impairment compared with antibiotic treatment alone, in patients with serum bilirubin >4 mg/dL or creatinine >1 mg/dL. ...

journal_title：Alimentary pharmacology & therapeutics

authors： Cartier M,Terg R,Lucero R,Muñoz A,Romero G,Levi D,Miguez C,Abecasis R

更新日期：2010-07-01 00:00:00

abstract：BACKGROUND:Gastro-oesophageal reflux disease (GERD) is one of the commonest diseases of Western populations, affecting 20 to 30% of adults. GERD is multifaceted and the classical oesophageal symptoms such as heartburn and regurgitation often overlap with atypical symptoms that impact upon the respiratory system and air...

journal_title：Alimentary pharmacology & therapeutics

authors： Pearson JP,Parikh S,Orlando RC,Johnston N,Allen J,Tinling SP,Johnston N,Belafsky P,Arevalo LF,Sharma N,Castell DO,Fox M,Harding SM,Morice AH,Watson MG,Shields MD,Bateman N,McCallion WA,van Wijk MP,Wenzl TG,Karkos

更新日期：2011-04-01 00:00:00

abstract：BACKGROUND:Antibiotic prophylaxis seems to decrease the incidence of bacterial infections in patients with cirrhosis and upper gastrointestinal bleeding and is considered standard of care. However, there is no updated information regarding the effects of this intervention. AIM:To assess the benefits and harms of antib...

journal_title：Alimentary pharmacology & therapeutics

authors： Chavez-Tapia NC,Barrientos-Gutierrez T,Tellez-Avila F,Soares-Weiser K,Mendez-Sanchez N,Gluud C,Uribe M

更新日期：2011-09-01 00:00:00

abstract：AIM:To assess the efficacy and tolerance of sodium alginate compared to cisapride in patients suffering from reflux symptoms, without severe oesophagitis. METHODS:A total of 353 patients with symptoms of reflux oesophagitis (average age 40 years, 51% men, 33% smokers, 43% consumers of alcoholic drinks) were selected a...

journal_title：Alimentary pharmacology & therapeutics

authors： Poynard T,Vernisse B,Agostini H

更新日期：1998-02-01 00:00:00